Real-world data from Italian diabetes centers shows oral semaglutide significantly improved blood sugar control, body weight, and cardiovascular risk markers after just three months.
3 monthsSignificant improvements in HbA1c, weight, and cardiovascular risk markers seen with oral semaglutide
What the researchers found
Oral semaglutide produced significant short-term reductions in HbA1c and body weight, along with improvements in cardiovascular risk markers, in a real-world type 2 diabetes population.
Why it matters
Most semaglutide data comes from controlled clinical trials with strict inclusion criteria. This real-world study confirms that the benefits translate to everyday clinical practice, and that even the oral formulation — not just injections — delivers meaningful results quickly.
The numbers in context
- 167 patients; mean age 66.5 years; baseline HbA1c 8.4%
- 83.2% on 7 mg dose
- HbA1c: 8.4% to 7.1% (-1.3%) in 3 months
- 30.5% lost more than 5% body weight (largest HbA1c drop: -1.9%)
- Significant cardiovascular risk reduction (p=0.04)
- Significant lipid parameter improvements
How the study worked
Multi-center real-world observational study across 4 Italian diabetes centers. Patients newly prescribed oral semaglutide were assessed at baseline and 3 months for glycemic control, weight, and cardiovascular risk parameters.
Who was studied
N=167 Italian adults with type 2 diabetes from 4 diabetes centers. Mean age 66.5, mostly obese, baseline HbA1c 8.4%. Three months of oral semaglutide.
What this study cannot tell us
Observational design without a control group; 3-month timeframe limits long-term conclusions; Italian patient population may not generalize globally; specific effect sizes not provided in abstract.
How to read the evidence
Real-world observational study providing moderate evidence. Supports clinical trial findings but lacks the rigor of randomized controlled trials.
When this study was published
Published in 2025 with current-era data on oral semaglutide prescribing.
The bigger picture
With global shortages of injectable GLP-1 drugs and growing demand, oral semaglutide represents a critical alternative. Real-world evidence of rapid effectiveness supports its broader adoption and may help address access challenges.
Questions still open
- Do these short-term improvements persist at 6 and 12 months in real-world settings?
- How does oral semaglutide compare to injectable semaglutide in head-to-head real-world studies?
- Are there patient subgroups that benefit more from oral versus injectable formulations?
Common questions
Is oral semaglutide as effective as the injectable version?
Why is real-world data important for medications?
Read the original research
Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.
Pharmaceuticals (Basel, Switzerland), 18(6)
Citation
Palazzi, Sara; Sentinelli, Federica; Zugaro, Antonella; Morgante, Sara; Santarelli, Livia; Melanzi, Sandra; De Mutiis, Annamaria; Piersanti, Deamaria; Macerola, Barbara; Iezzi, Marco; Mercuri, Pietro; Ferranti, Alessandro; Tienforti, Daniele; Cavallo, Maria Gisella; Barbonetti, Arcangelo; Baroni, Marco Giorgio. (2025). Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.. Pharmaceuticals (Basel, Switzerland), 18(6). https://doi.org/10.3390/ph18060856